Healthcare professionals and policymakers should understand how pharmaceutical companies exploit patent systems to maintain drug monopolies. The analysis identifies three primary tactics: filing hundreds of patents on minor modifications, leveraging regulatory capture to approve low-innovation applications, and creating legal barriers that make generic market entry financially prohibitive.
These strategies have direct clinical consequences. Evergreening extends monopolies for decades, inflating medication costs and limiting patient access to affordable treatments. When companies file numerous patents on trivial changes—such as switching from twice-daily to once-daily dosing—patent offices often approve applications that provide minimal therapeutic benefit but reset exclusivity clocks. The result is a healthcare system where innovation claims mask monopolistic behavior, diverting resources from genuine drug development.
Understanding these mechanisms is essential for advocates pushing patent reform, healthcare administrators negotiating drug prices, and clinicians counseling patients about medication affordability.
Read the full article on GMJ Newsroom.
Was this article helpful?
